Christoph S. Klade
Vienna, 1190, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Pharmacokinetics of Landiolol and Its Metabolite M1 During Renal Replacement Therapy in Septic Shock Patients: A Sub-Study of the Landi-SEP Trial.
Journal: European journal of drug metabolism and pharmacokinetics
Published: October 07, 2025
A multicentre observational study on landiolol use, efficacy, and safety in European patients with supraventricular arrhythmia (Landi-UP).
Journal: European heart journal. Acute cardiovascular care
Published: August 04, 2025
Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV).
Journal: HemaSphere
Published: January 28, 2025
Landiolol is effective and safe in paediatric supraventricular tachycardia: evidence from a European prospective multicentre open-label phase III study (LANDI-PED).
Journal: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
Published: November 19, 2024
Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP).
Journal: Intensive care medicine
Published: March 12, 2024
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Journal: Annals of hematology
Published: January 12, 2024
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b.
Journal: Leukemia
Published: December 25, 2021
Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups.
Journal: HemaSphere
Published: April 14, 2020
Last Updated: 09/26/2026